Outcome of Board Meeting

November 04, 2026 BSE Limited National Stock Exchange of India Limited Corporate Relation Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block - G Dalal Street Bandra-Kurla Complex Mumbai – 400001 Bandra (East), Mumbai - 400051 Scrip Code: 524404 Symbol: MARKSANS Sub: Outcome of Board Meeting Dear Sir/Madam, Pursuant to Regulation 33 and Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”) and other regulations, if applicable, we enclose herewith the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2026 approved by the Board of Directors of the Company at its Meeting held today i.e. November 04, 2026 along with Limited Review Reports thereon. Pursuant to Regulation 33 of the Listing Regulations as amended, we hereby declare that M/s. MSKA & Associates LLP, Chartered Accountants, the Statutory Auditors of the Company have submitted the Limited Review Reports for Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30, 2026 with an unmodified opinion. The aforesaid information is also available on the website of the Company at http://www.marksanspharma.com/quarterly-results.html The meeting commenced at 12:10 p.m. and concluded at 01:20 p.m. We request you to note the aforesaid in your records. Thanking you. Yours faithfully For Marksans Pharma Limited Harshavardhan Panigrahi Company Secretary Enclosed as above Marksans Pharma Ltd. 11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000 E-mail: companysecretary@marksanspharma.com www.marksanspharma.com MSKA & Associates LLP o Flor6, Rahesa Tianium (Formerly known as M S K A & Associates) \é@ftemcixlpress :ighnvay, GeGetaniali © Chartered Accountants by 40o0l0on6y3,, IRNaDmI A Nagar, Gore&g aon Tel: +91 22 6974 0200 Independent Auditor’s Review Report on Standalone unaudited financial results of Marksans Pharma Limited for the quarter and year to date pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. To The Board of Directors of Marksans Pharma Limited 1. We have reviewed the accompanying statement of standalone unaudited financial results of Marksans Pharma Limited (hereinafter referred to as ‘the Company’) for the quarter ended 30 September 2026 and the year to-date results for the period from 01 April 2026 to 30 September 2026 (‘the Statement’) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (‘the Regulations’). 2. This Statement, which is the responsibility of the Company’s Management and has been approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’, prescribed under Section 133 of the Companies Act, 2013 (‘the Act’) read with relevant rules issued thereunder (‘Ind AS 34’) and other recognised accounting principles generally accepted in India and is in compliance with the Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 and other recognised accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of the Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For M S K A & Associates LLP (Formerly known as M S K A & Associates) Chartered Accountants ICAl Firm Registration No.105047W/W101187 Nitin Tiwari Partner Membership No.: 118894 UDI\b NAy A:HLY 2Y K h6 by Place: Mumbai Date: 04 November 2026 Registered Office: 602, Raheja Titanium, Western Express Highway, Goregaon (East), Mumbai-400063, Maharashtra, India Tel: +91 22 6974 0200 | LLPIN: ACT-3789 Ahmedabad | Bengalury | Chandigarh | Chennai | Coimbatore| Goa | Gurugram | Hyderabad | Kochi | Kolkata| Pune www.mska.in suero pexeT NTETREME[ 12 J5 )vnaua@( ys L0ESEE .LY'V50°06 s'ozvZ L8092 8268 tze lez evzco TL LOSEVOS EEISVE %4( tLo 5Sb 608°v5 €¢0056B LE61 ]e'so( Lo E%0LLC6 YSEL9 10°096'6v 9'9v 99€ 3a91 N030 599120 O2 5 nnvnauza(| s'voies 90166 L00EILY 6L yeLev )89v( 59€°90 82 Loorv LLLHTS S'15€°0L +85094 eserE DX z0S LL89Z 20( 051 )!'so( yT9AE ySE'Lo eze ezo x V¥ F lU HV14 5¢ 90 19 nnvnauaa([ s'E066L LVLUS L°06LOY 61291 82606 )156( 9881 92 l829 LLzzvB S'160E£ L'609LL 5068 )0+o{ L00¥ ¢9062 L'SvGL6 95 ]122( .sz0 F'55066 yse'Lo e e 001202 5 vnauaa( ezovyL 581786 ELB9'E0 L'res'or 20689 212€( 28'59 eis 819 SYVE£ T518L LTIV6E 208'05 - L 71981 86805 )t'00( 029 )052£[ EZ 861 yse'1o e zco 5 0nn NV813¥ 3N03 o2 a9 )nnvnau3@( zB lVo C°889°51 Lvove Lz 89 0 )18'ze( euLs ero ] r6voz V8166 6058 TLE60 }010o( 0 T21 96067 e'va 0g( 90 86761 ysE'Lo 2 L S2 80 2 W5 vnat3@ ( E'LEBov STV eI0 L'Y69L8 e lo'ev 82059 e 6050 96289 TLOBEP L°00Z4£ LE2°08 69€ STTEV[ 8ss'rZ E'v6 ]07g6( 790 ss8oz yse'Lo 196 138 0 1 5 LVALIDNIVYS odssegous |y yso aw euna l |uo O o I) i U u w u B0 au oj ‘0 Jo j s1 3( ) 1+ uz o( ows y0= |3xdsuses ous wn ew la d |up 0e 0i ss 10j SIORSIU- |I de nP i2 ow eo sJ a Oi ]E SUs0 aouO SJap pS' SIORPUIEPS |EUp axdsus a qeu ay |y ss wdokas |dt u0 eo us oi ss ee wvd o a i |u s gs aea d‘ g :o au pe eu gp ou exdsu sas OI 3x d (a Lou is elas |8 d0 u 0 o) y 1 W¢ e- av x( Lex axdausos )€( )nisujlex |)) q(niau y}e x )ae oil iad Jauop geja i )0 u (y ae px Lexa x |ld os ieu jse |du oy wuo sp e) ¥5:9( DOWAIR )Y OI IU] US PU JIo A0 IW2 . 8 |9 }I aL } wS U SS U0 II G (11 Y 3 A}01 PO0 0 14 Dd W| Re IR R P IU L3 } A1 UB O IJ S |e X 0E UQ0A2 |OIUBJ DOWdIBYBusaa U02 )2+8 ( ) u gd oo ww da iayausns |L0ij |d e 3 ls b pD y n ne e y d) dA r A) e B j 0 ( ne 3eo |y |a ob in ui of |3es ls ubs d Bny a se u s3 1 A02 38 . J1. ) MM L 2 © Y 8 G 3 o © b S 9 £ 8 6 10 tL kz YINEVHY SNYSHEVIN $9£9900TLHIdNOZH 6526T £50007-{eqUINY ‘(153/] HAYPUY ‘eIeMISO ‘PEOY UOISUDIXI (ESAQ £J09A INAPUEIS ‘4001 B3O PaIalsIBay wodeueyW dAIseieu100e8usedwyod euLIRYdSURSYIMEMMW :SUSGIM ‘000Z 005220 "N duoydajal 9202 ¥3BW3LJTS G3ANI HVIA 4TVH HILHVND SLINSIY TVIONVNIA G3LIANYNN INOTWANYLS 40 LNIWILYLS MARKSANS PHARMA LIMITED STANDALONE UNAUDITED STATEMENT OF ASSETS AND LIABILITIES " _(zinmillion ) Particulars As at As at 30Sept2026 | 31 Mar 2026 (UNAUDITED) (AUDITED) ASSETS Non-current assets Property, plant and equipment 3,614.87 3,686.75 Right of use assets. 260.89 275.23 Other intangible assets 48.87 17.59 Financial assets Investments 3,730.78 267213 Other financial assets 12.07 11.46 Other non-current assets 197.26 175.54 Non Current tax assets (net) 8.25 10.81 Total non [Showing first 8,000 characters — download PDF for full document]